SARAH PAI: Open Payments
NPI 1255762167 · SAN DIEGO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$323 in 14 payments from 8 companies in 2025. Trend: 2023 $358 · 2024 $778 · 2025 $323
Food & beverage: $323
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 3 | $73 |
| Vanda Pharmaceuticals Inc. | 2 | $58 |
| Otsuka America Pharmaceutical, Inc. | 2 | $49 |
| Alkermes, Inc. | 2 | $45 |
| Lundbeck LLC | 2 | $42 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $20 |
| Teva Pharmaceuticals USA, Inc. | 1 | $20 |
| Janssen Pharmaceuticals, Inc | 1 | $16 |
Products named: INGREZZA, FANAPT, ABILIFY ASIMTUFII, ARISTADA, REXULTI, CAPLYTA, AUSTEDO XR, INVEGA SUSTENNA.
Industry payments across CA — which companies pay providers there.
